Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orencia

- PMLiVE

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

Combination regimen didn't improve progression-free survival

- PMLiVE

FDA approves Recordati’s Cushing disease drug Isturisa

Important new treatment option for patients with rare disorder

- PMLiVE

FDA approves Allergan’s biodegradable glaucoma implant drug

Reduces intraocular pressure in glaucoma or ocular hypertension

- PMLiVE

Trevena gets second go at FDA approval for pain drug

FDA sets review completion date of 7 August 2020

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

BMS partners with Voluntis to co-develop oncology digital therapeutics

Aims to create a mobile app to help patients self-manage their symptoms

- PMLiVE

Biohaven gets FDA approval for migraine drug Nurtec ODT

Becomes second drugmaker to bring an oral CGRP inhibitor to US market

- PMLiVE

Raising awareness and encouraging support on Rare Disease Day 2020

Rare Disease Day takes place on 29 February around the world

- PMLiVE

Acacia finally gets FDA okay for first product Barhemsys

Edison analyst predicts drug could reach $387m at peak

- PMLiVE

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

Advisory committee voted 6-5 in favour of drug

- PMLiVE

Coronavirus outbreak escalation could impact drug supply chain

Concerns raised that the virus could cause shortages

- PMLiVE

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links